. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2020 Feb 27;20(7):438–444.e1. doi: 10.1016/j.clml.2020.02.001

Table 3:

Arthralgias/Myalgias Management and Outcomes

Arthralgias/Myalgias Management and Outcomes (n=76)
	Intervention	Improved	Discontinued
No Change in Management	47% (35/76)	19% (19/35)
Dose Reduction	42% (15/41)	60% (9/15)	13% (2/15)
Ibrutinib Hold	17% (7/41)	40% (1/7)	28% (2/7)
Hold and dose reduction	29% (12/41)	8% (1/12)	83% (10/12)
Discontinued without re-challenge	17% (7/41)

References:

^1.

Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.